Categories AlphaGraphs, Consumer, Earnings
Earnings: Everything you need to know about Nike’s Q2 2023 results
Sportswear giant Nike, Inc. (NYSE: NKE) on Tuesday reported a modest increase in earnings for the second quarter of 2023, when its revenues grew in double digits. The latest numbers also came in above Wall Street’s expectations.
Second-quarter net income was $1.33 billion or $0.85 per share, compared to $1.33 billion or $0.83 per share in the corresponding period of fiscal 2022. The bottom line was negatively impacted by an increase in operating expenses.
November-quarter revenues grew 17% from last year to $13.3 billion. The top line also came in above the consensus forecast.
Check this space to read management/analysts’ comments on Nike’s Q2 2023 earnings
“Consumer demand for NIKE’s portfolio of brands continues to drive strong business momentum in a dynamic environment. We remain focused on what we can control, and we are on track to deliver on our operational and financial goals — setting the foundation for sustainable, profitable growth,” said Matthew Friend, chief financial officer of Nike.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications